Literature DB >> 12650784

Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials.

Jianping Liu1, Eric Manheimer, Kiichiro Tsutani, Christian Gluud.   

Abstract

OBJECTIVE: The aim of this study was to assess beneficial and harmful effects of medicinal herbs for hepatitis C virus (HCV) infection.
METHODS: The databases of the Cochrane Collaboration, MEDLINE, EMBASE, and BIOSIS were searched combined with manual searches of five Chinese and one Japanese journals. We included randomized trials comparing medicinal herbs with placebo, no intervention, nonspecific treatment, other herbs, or interferon and/or ribavirin. Trials of herbs with or without other drug(s) were included. Methodological quality of the trials was evaluated by randomization, double blinding, and the Jadad scale.
RESULTS: Thirteen randomized trials (n = 818) evaluated 14 medicinal herbs. Four trials had adequate methodology. Compared with placebo, none of the herbs showed effects on HCV RNA or liver enzyme, except for silybin, which showed a significant reduction of serum AST and gamma-glutamyltranspeptidase levels in one trial. Oxymatrine showed effects on clearance of HCV RNA (relative risk = 9.20, 95% CI = 1.26-67.35) compared with vitamins. The herbal mixture Bing Gan Tang plus interferon-alpha showed better effects on clearance of HCV RNA (relative risk = 2.54, 95% CI = 1.43-4.49) and on normalization of serum ALT (relative risk = 2.54, 95% CI = 1.43-4.49) than interferon-alpha alone. The herbal mixture Yi Zhu decoction showed better effects on clearance of HCV RNA and normalization of ALT compared with glycyrrhizin plus ribavirin. Yi Er Gan Tang showed effects on normalizing serum ALT compared with silymarin plus glucurolactone. The herbs were associated with adverse events.
CONCLUSIONS: There is no firm evidence supporting medicinal herbs for HCV infection, and further randomized trials are justified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12650784     DOI: 10.1111/j.1572-0241.2003.07298.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  26 in total

1.  Effect of oxymatrine on hepatic gene expression profile in experimental liver fibrosis of rats.

Authors:  Yi-cheng Jian; Wei Li; Yi He; Ming Jiang; Yan-bing Liu; Wu-jun Xiong
Journal:  Chin J Integr Med       Date:  2012-07-22       Impact factor: 1.978

2.  Effects of oxymatrine on experimental hepatic fibrosis and its mechanism in vivo.

Authors:  Guang-Feng Shi; Qian Li
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

3.  Capsule oxymatrine in treatment of hepatic fibrosis due to chronic viral hepatitis: a randomized, double blind, placebo-controlled, multicenter clinical study.

Authors:  Yi-Min Mao; Min-De Zeng; Lun-Gen Lu; Mo-Bin Wan; Cheng-Zhong Li; Cheng-Wei Chen; Qing-Chuen Fu; Ji-Yao Wang; Wei-Min She; Xiong Cai; Jun Ye; Xia-Qiu Zhou; Hui Wang; Shan-Ming Wu; Mei-Fang Tang; Jin-Shui Zhu; Wei-Xiong Chen; Hui-Quan Zhang
Journal:  World J Gastroenterol       Date:  2004-11-15       Impact factor: 5.742

4.  Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial.

Authors:  Ezra Gabbay; Ehud Zigmond; Orit Pappo; Nila Hemed; Mina Rowe; George Zabrecky; Robert Cohen; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2007-10-28       Impact factor: 5.742

Review 5.  Complementary and alternative medications in hepatitis C infection.

Authors:  Dina L Halegoua-De Marzio; Jonathan M Fenkel
Journal:  World J Hepatol       Date:  2014-01-27

6.  Oxymatrine therapy for chronic hepatitis B: a randomized double-blind and placebo-controlled multi-center trial.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; Mo-Bin Wan; Cheng-Zhong Li; Cheng-Wei Chen; Qing-Chun Fu; Ji-Yao Wang; Wei-Min She; Xiong Cai; Jun Ye; Xia-Qiu Zhou; Hui Wang; Shan-Ming Wu; Mei-Fang Tang; Jin-Shui Zhu; Wei-Xiong Chen; Hui-Quan Zhang
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

7.  Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.

Authors:  Michele Malaguarnera; Massimo Motta; Marco Vacante; Giulia Malaguarnera; Filippo Caraci; Giuseppe Nunnari; Caterina Gagliano; Carmela Greco; Giuseppe Chisari; Filippo Drago; Gaetano Bertino
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

8.  Inhibitory effect of oxymatrine on serum hepatitis B virus DNA in HBV transgenic mice.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Jing-Yuan Fang; Yu-Lin Song; Zhao-Hui Shen; Ai-Ping Cao
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

9.  The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study.

Authors:  Carmela Loguercio; Alessandro Federico; Marco Trappoliere; Concetta Tuccillo; Ilario de Sio; Agnese Di Leva; Marco Niosi; Mauro Valeriano D'Auria; Rita Capasso; Camillo Del Vecchio Blanco
Journal:  Dig Dis Sci       Date:  2007-04-05       Impact factor: 3.199

10.  Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial.

Authors:  Michael W Fried; Victor J Navarro; Nezam Afdhal; Steven H Belle; Abdus S Wahed; Roy L Hawke; Edward Doo; Catherine M Meyers; K Rajender Reddy
Journal:  JAMA       Date:  2012-07-18       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.